Background: Vascular progenitor cells (VPCs) facilitate angiogenesis and initiate vascular repair by homing in on sites of damage and adhering to extracellular matrix (ECM) proteins. VPCs also contribute to tumor angiogenesis and induce angiogenic switching in sites of metastatic cancer. In this study, the binding of attaching cells in VPC clusters that form in vitro on speci c ECM proteins was investigated.
Endothelial-like vascular progenitor cells (VPCs) can be isolated or expanded from hematopoietic cell sources including bone marrow, umbilical cord blood (UCB) and peripheral blood (PB). Enumerating vascular clusters according to the method of Hill et al. [1] from these blood-derived cell sources correlates with important health outcomes in multiple settings, including patients at risk for cardiovascular events [2, 3] , critically ill patients with severe organ dysfunction [4] [5] [6] and in cancer patients undergoing hematopoietic stem cell transplantation [7, 8] or radiation treatment [9] . Changes in VPC cluster number and character may be used to characterize cell sources for vascular repair capacity. In addition, interventions aimed at augmenting regenerative capacity such as the administration of cytokines, growth factors or medications to mobilize vascular progenitors may be monitored and evaluated using the VPC assay.
VPC clusters form by the aggregation of monocytes and lymphocytes on spindle-shaped attaching cells with monocytoid and endothelial features [10] [11] [12] . Moreover, during ex vi o expansion of endothelial colony-forming cells (ECFCs) used in therapeutic vascular repair, endothelial-like cells rst attach to extracellular matrix proteins and form spindle-shaped cells [13] . Cell populations enriched for angiogenic precursors such as CD133-selected or CD14-selected cells also form attached spindle-shaped cells on ECM proteins in vitro, suggesting that interactions between vascular precursors and the ECM is an important initiating step.
VEGF-mediated binding to bronectin may play an important role in the homing of angiogenic precursors to sites of tissue injury or metastatic cancer in vi o [14] . Interestingly, VEGF is o en increased in cancer patients [15] [16] [17] and contributes to increased tumour angiogenesis. Cell attachment to bronectin and to other extracellular matrix proteins is facilitated by speci c integrins, which are cell surface heterodimers that initiate intracellular signaling cascades a er binding to the ECM. e extracellular matrix in sites of tumor involvement is extensively remodeled and highly enriched for bronectin [18] [19] [20] and collagen I [21] [22] [23] when compared to that from the matrix environment in healthy or healing tissue which is typically enriched for laminin [24] and collagen IV [25] . e role of ECM proteins, therefore, may in uence the homing of vascular precursors in response to angiogenic signals such as VEGF and may preferentially direct angiogenic precursors to sites of tumor involvement. e extent to which angiogenic precursors preferentially contribute to tumor growth at metastatic sites may depend on their capacity to attach to tumourspeci c microenvironments, including cancer-speci c ECM proteins. Strategies to guide angiogenic precursors to sites of healing tissue, damaged in cancer patients a er surgery or caused by chemotherapy or radiation, are needed to ensure that tissue regeneration does not lead to angiogenic switching and growth of the underlying cancer.
In this report, di erential ECM-binding pro les of angiogenic precursors from patients with cancer compared to normal controls are described. Furthermore, the pattern of cell surface integrin expression from these patients is speci c for particular ECM proteins and may be informative regarding the readiness of vascular repair mechanisms and the risk of vascular switching in cancer patients. Moreover, enhanced binding of angiogenic precursors to bronectin in cancer patients was con rmed to be mediated by VEGF through speci c interactions with integrin α5β1. Our observations provide a foundation for developing regenerative therapies in cancer patients with the goal of promoting healing of normal tissues without stimulating new vessel growth at sites of micrometastases.
Methods

Sample collection
Blood samples were obtained following informed consent and in accordance with protocols approved by the institutional research ethics board at e Ottawa Hospital. Mononuclear cells (MNCs) were isolated from blood samples from controls and from pre-operative samples from adult patients with oral cancer and peripheral blood from adult patients with nonHodgkin's lymphoma. Peripheral blood samples were collected in 7 mL sterile vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA).
Cell preparation and isolation
MNCs were isolated using Ficoll density centrifugation. Blood samples were diluted 1:1 with sterile 1X phosphate-bu ered saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA) with 2% fetal calf serum (FCS) (Invitrogen Canada Inc., Burlington, ON, Canada) and overlaid onto Ficoll-Paque Premium (GE Healthcare, Uppsala, Sweden) and centrifuged at 1500 rpm at 20°C for 30 minutes. MNCs were subsequently collected and washed three times with 1XPBS with 2% FCS and centrifuged for 30 min.
Vascular progenitor cell cluster assay (CFU-Hill)
VPC assays were performed in accordance with the methods described by Hill et al. [1] . VPCs were cultured using the EndoCult Liquid Medium Kit (StemCell Technologies, Vancouver, BC, Canada) as stated in the manufacturer's protocol.
Labonté et al. Vascular progenitors and ECM binding in cancer
MNCs were resuspended in complete EndoCult medium and seeded at 5x10 6 cells/well on 6-well matrix pre-coated tissue culture plates (coated with either bronectin, collagen I, collagen IV or laminin) (BD Biosciences, Mississauga, ON, Canada). Plates were then placed in a 37°C humidi ed incubator with 5% CO 2 in air. A er 48 hours, wells were gently rinsed with media and non-adherent cells were collected and re-plated at 10 6 cells/well on 24-well matrix-coated tissue culture plates (coated with either bronectin, collagen I, collagen IV or laminin) (BD Biosciences), and incubated for an additional 3-5 days. VPC cluster formation was quanti ed by enumerating the number of clusters formed on each matrix using an inverted microscope. All values are reported as the mean number of VPC clusters observed/ mL of blood collected prior to Ficoll gradient centrifugation.
Immunohistochemistry
VPC clusters were analyzed by immunohistochemistry for cell surface integrin expression. Media in the wells of the matrixcoated tissue culture plates was removed and the remaining attached VPC clusters were gently washed and xed for 10 minutes at 4°C and washed again. Cells were incubated with a blocking solution for 20 minutes at room temperature and incubated for 1 hour at room temperature with primary antibody diluted in incubation bu er (2%FCS diluted in 1X PBS). e following primary antibodies were used: mouse anti-human α5 conjugated to Phycoerythrin (PE) antibody and β1 conjugated to Fluorescein isothiocyanate (FITC) antibody (diluted 1:100), α2β1 conjugated to FITC antibody (1:100), α3β1 antibody (1:100) (all antibodies from Life Span Biosciences Inc, Seattle, WA, USA). Controls were performed in parallel by incubating with no primary antibody or with an isotype control of mouse immunoglobulin G (IgG) antibody (1:100) (IgG 1k, BD Biosciences). Controls were also washed and incubated for 1 hour at room temperature with secondary antibody diluted in incubation bu er. Secondary antibodies against mouse were conjugated to FITC or Texas Red (1:100) (Invitrogen, Eugene, OR, USA). Cells were washed and incubated with 1mL of 4' , 6-diamidino-2-phenylindole (DAPI) (Pierce Biotechnology Inc., USA) for 1 minute at room temperature. Cells were then mounted with 1-2 drops of DAKO mounting media (Dako North America Inc., Carpinteria, CA, USA) and visualized using the Zeiss Observer.Z1 inverted microscope where images were captured with the AxioCam HRm camera by Zeiss.
Inhibiting integrin function
MNCs were isolated fromthree samples of peripheral blood from healthy volunteers. Each sample was divided into four treatment types and cells received media containing either of the following: neutralizing antibody against α5β1 integrin (clone JBS5, Millipore, Billerica, Massachusetts, USA), neutralizing antibody against α2β1 integrin (clone BHA2.1, Millipore), mouse anti-human IgG (IgG 1k, BD Biosciences) (control) or no treatment (control). Antibodies were diluted to a concentration of 10 ug/mL as per manufacturer's protocol. Cells were then plated on bronectin or laminin in the presence of the same antibody conditions throughout the VPC culture period.
VEGF studies
VEGF ELISA: An enzyme-linked immunosorbent assay (ELISA) for VEGF (R&D Systems, Minneapolis, MN, USA) was performed using plasma from healthy controls, patients with oral cancer, patients with lymphoma and patients with acute kidney injury, in accordance with the manufacturer's protocol. All samples were tested in duplicate. A standard curve of VEGF concentrations was generated using eight standard VEGF solutions provided by the manufacturer ranging from 0-2000 pg/mL against which our plasma samples of unknown VEGF levels were tested and from which VEGF concentrations were interpolated. To compare and analyze plasma VEGF concentrations, a Student's t-test was used.
Anti-VEGF treatment: VPC assays were performed using MNCs from two cord blood samples and two pre-operative peripheral blood samples from patients with oral cancer and plated on bronectin-or laminin-coated 6-well tissue culture plates. Half of each sample was treated with bevacizumab (Genentech Inc, San Francisco, CA, USA), a di usible VEGF inhibitor introduced to block the e ects of VEGF in VPCmatrix interactions. Cells were incubated for 24 hours with 1ug/mL of bevacizumab prior to being plated on bronectin or laminin. Bevacizumab remained in the media throughout the entire VPC culture period.
VEGF supplementation: VPC assays were performed using cells from ve healthy adult peripheral blood samples that were plated on bronectin-or laminin-coated 6-well tissue culture plates. Each sample was divided into two, and mononuclear cells were incubated with either 0 or 1 ug/mL of human recombinant VEGF165 (BD Biosciences, Mississauga, ON, Canada) in sterile 1XPBS (Sigma-Aldrich, St. Louis, MO, USA) for 24 hours prior to being plated on bronectin or laminin. Following incubation, the cells receiving VEGF were grown in the media containing the VEGF throughout the entire VPC culture period.
Statistical analyses
Data are expressed as mean ± standard error of the mean (SEM). Statistical signi cance was determined using an unpaired, two-tailed Student's t-test with a signi cant value of p< 0.05, except for the ow data which was analyzed using a paired, two-tailed Student's t-test. GraphPad Prism version 5.00 (Graphpad So ware, San Diego, California) for Windows was used for statistical analysis.
Results
VPC clusters on di erent extracellular matrix proteins in cancer patients
To better understand the status of cells that give rise to VPC clusters in patients with cancer, VPC clusters were measured on ECM proteins that are more typical of cancer environments and compared the cluster formation on ECM proteins that are typical of normal remodeling tissue. VPC clusters from peripheral blood (PB) samples of healthy controls (n=10) were more numerous when plated on laminin (31.6 ± 6.5 clusters/mL PB) compared with any of the other matrices tested ( bronectin: 8.5 ± 0.7 clusters/mL PB, p=0.02; collagen I: 6.9 ± 1.3 clusters/mL PB, p=0.03; and collagen IV: 6.1 ± 2.0 clusters/ mL PB, p=0.04) (see gure 1). VPC clusters were also enumerated using a similar panel of matrix proteins and PB samples from patients with cancer. VPC clusters from pre-operative PB samples from patients with oral cancer (n=4) were more abundant when cells were plated on bronectin (42.1 ± 8.1 clusters/ mL) compared with the other three matrices (laminin: 7.5 ± 8.2 clusters/mL, p=0.01; collagen I: 3.7 ± 1.3 clusters/mL, p=0.03; collagen IV: 7.8 ± 4.0 clusters/mL, p=0.02). Similarly, PB samples from patients with lymphoma (n=5) yielded increased VPC clusters on bronectin (86.5 ± 13.8 clusters/mL) compared with the other matrices (laminin: 27.9 ± 10.1 clusters/mL, p=0.003; collagen I: 39.6 ± 7.5 clusters/mL, p=0.01; and collagen IV: 11.9 ± 1.9 clusters/mL, p=0.004).
Taken together, our observations suggest that VPC cluster formation can occur to varying degrees on di erent matrix proteins with a pro le that is speci c for patients with cancer in comparison to healthy controls. In particular, preferential VPC cluster formation on bronectin with no accompanying increase in VPC cluster formation on laminin was associated with patients with oral cancer and lymphoma. Moreover, can- cer patients had increased overall levels of VPCs. In contrast, a distinct VPC binding pro le was observed in steady state controls with more abundant cluster formation on laminin compared with the other ECM proteins. Although the pro le of VPC cluster formation di ers between patients with cancer and healthy controls, the absolute levels of VPC clusters on any one matrix did not allow us to distinguish between the groups. e clinical characteristics of the study subjects are summarized in Table 1 . While gender was similar for the various categories of subjects enrolled in this study, patients and controls di ered signi cantly with regards to age and prior chemotherapy or radiation exposure.
Attaching cells in VPC clusters bind bronectin and laminin via speci c integrins
e di erent binding pro les of VPC clusters from healthy controls and from cancer patients can be distinguished using bronectin and laminin alone as an abbreviated matrix panel based on our initial results described above. Fibronectin and laminin, therefore, were used for subsequent studies to address factors involved with VPC cluster formation on di erent matrix proteins. e role of integrins in the initial stage of cell attachment during VPC cluster formation was then investigated.
Integrins α5β1 [26] [27] [28] , α2β1 [29, 30] and α3β1 [30, 31] were selected to address the role of speci c integrin-mediated binding of attaching cells in the VPC clusters. Integrin α5β1 binds to bronectin and not laminin, while α2β1 integrin binds to laminin and not bronectin and both integrins have been associated with angiogenesis. e α3β1 integrin binds to both laminin and bronectin.
Immunohistochemistry was used to assess cell surface expression of integrins in VPC clusters. Attaching cells in VPC clusters derived from samples of healthy volunteers and plated on bronectin expressed α5β1 integrin but not α2β1 (see gure 2). α2β1 integrin was present on attaching cells in VPC clusters plated on laminin derived from the same samples while α5 integrin expression was negative. e expression of α3β1 was ob- * TNM staging refers to tumor size (T), presence of no odes (N) and metastases (M).
FIGURE 2. Representative 6 day old VPC clusters formed om
MNCs isolated om a peripheral blood sample om a healthy olunteer. Cells were plated on bronectin (a) and expressed α5 integrin (b), and β1 integrin (b inset). Clusters on bronectin were negative for α2β1integrin (c) and positive for α3β1 integrin (d). Isotype controls were negative (insets). Cells were plated on laminin (e-h) and expressed α2β1 integrin (g). Clusters were negative for α5 integrin (f ) on laminin but positive for α3β1 (h). Isotype controls were negative (insets).
served on the cell surface of attaching cells in VPC clusters derived from healthy donors when plated on both laminin and bronectin. is data suggests that populations of cells with the appropriate integrin repertoire and the capacity to form VPC on both bronectin and laminin are present in healthy donors, but taken together with our previous observations, the relative frequency of bronectin -binding or laminin-binding integrin pro le appears to shi .
To assess whether integrin mediated binding of attaching cells is required for VPC cluster formation, VPC assays were performed in the presence of inhibiting antibodies against α5β1 and α2β1 integrins. VPC assays were performed using MNCs isolated from PB of healthy controls and plated onbronectin and laminin in the presence or absence of anti-α5β1, anti-α2β1, or polyclonal IgG. VPC cluster levels were reported as a ratio compared with the number of clusters observed in controls lacking antibody. VPC clusters on bronectin were markedly reduced in the presence of anti-α5β1 antibody (25 ± 16% of controls, p=0.008) whereas anti-α2β1 and non-speci c IgG had no e ect on VPC cluster number on bronectin (111 ± 28.9% and 110 ± 19.5% of controls, respectively, p=NS) ( Figure 3A) . Similarly, reduced number of VPC clusters were observed when cells were incubated with anti-α2β1 antibody and plated on laminin (2.8 ± 18.8% of controls, p=0.03) whereas anti-α5β1 and non-speci c IgG had no e ect on VPC cluster number on laminin (123 ± 24% and 104 ± 28.5% of controls, respectively, p=NS) ( Figure 3B ). Together, these observations support the important role of integrin-speci c binding to extracellular matrix proteins during VPC cluster formation.
VEGF enhances VPC cluster formation on bronectin
Prior studies report that cancer patients have increased plasma VEGF levels that correlate with worse prognosis and increased likelihood of metastasis [15] [16] [17] . Moreover, as VEGF can modulate α5β1 signalling [27] , it may directly contribute to increased levels of α5β1 expressing cells that in uence VPC cluster formation. Plasma VEGF levels were measured in our patients and the association of these levels with VPC cluster number on bronectin were assessed.
Healthy controls had lower plasma VEGF concentrations (75.6±13.6 pg/mL) than patients with oral cancer (210.7±38.0 pg/mL, p=0.01) or lymphoma (261.0±66.7 pg/ mL, p=0.02). Concerning patients with cancer, plasma VEGF levels were similar between patients with oral cancer and lymphoma (p=0.5). Furthermore, VPC assays performed in the presence of bevacizumab, a soluble VEGF-inhibitor, and plated on bronectin completely abrogated cluster formation in healthy controls (0±0 clusters/mL vs. 27.5 ± 1.5 clusters/mL in controls) and markedly reduced VPC clusters from PB samples of patients with oral cancer (10.5 ± 1.5 clusters/mL vs. 150 ± 5 clusters/mL) ( Figure 4) . Cells from the identical samples incubated with bevacizumab and plated on laminin did not reduce VPC cluster numbers. Next, MNCs from PB of healthy controls were exposed to elevated levels of VEGF and assessed the pro le of VPC formation on bronectin and laminin to address whether a pattern of increased VPC formation on bronectin could be induced by VEGF. Increased numbers of VPC clusters were observed using MNCs from healthy control subjects incubated with VEGF (1 ug/mL) when plated on bronectin compared to controls without VEGF (167 ± 33 clusters/mL vs. 79 ± 29 clusters/mL, p=0.04). MNCs isolated from healthy peripheral blood samples did not produce greater numbers of VPC clusters on laminin when incubated with high levels of VEGF compared to controls without VEGF (67 ± 16 clusters/mL vs. 69 ± 12 clusters/mL, p=0.9).
Discussion
Our results from this small study highlight the role of speci c integrin-mediated interactions with proteins of the extracellular matrix during the attachment of spindle-shaped cells in VPC cluster formation. Further, enhanced cluster formation on bronectin, mediated by integrin α5β1 binding, was observed in patients with oral cancer and lymphoma whereas greater cluster formation on laminin, mediated by integrin α2β1 binding, was preferentially observed in control subjects. Our data demonstrate that enhanced VPC cluster formation on bronectin is facilitated by VEGF and that blocking VEGF abrogates cluster formation on bronectin but has no e ect on cluster formation on laminin. Taken together, our work has identi ed an apparent pattern of VPC cluster formation on ECM proteins that may be speci c to cancer and di ers from healthy controls. Although more study is needed in a broader range of tumor types and stage of disease, our results may encourage the development of strategies to selectively block vascular progenitor recruitment to sites of tumor involvement without interfering with normal repair mechanisms by targeting VEGF-mediated changes in angiogenic attaching cells.
Consistent with our observations that VEGF enhances VPC cluster formation on bronectin, VEGF elaborated by tumors may facilitate vascular precursors and hematopoietic cells with angiogenic potential to tumor microenvironments that are enriched for bronectin, likely via VEGFR-1 and/or VEGFR-2 mediated cell interactions with speci c integrins [32] [33] [34] . Once VPCs are in close proximity to bronectin-rich tissues, cells expressing α5β1 integrin may bind to bronectin and produce signals that initiate angiogenesis [28] . Fibronectin and VEGF are key regulators of blood vessel growth, an observation that is supported by gene deletion studies that con rm bronectin and VEGF, as well as their receptors α5β1 integrin and VEGFR-2, are critical for vascular development [14] . Endothelial cells (ECs) respond to growth factors like VEGF and are modulated by the signals conveyed from integrins, which o en re ect the conditions of the extracellular milieu [35] . Consequently, the local combination of extracellular matrix proteins and the type and density of integrins expressed by cells attracted to a speci c tissue site can modulate EC responses to growth factors [35, 36] . Indeed, activation of α5β1 integrin by VEGFR-2, in the presence of VEGF, appears to facilitate binding to bronectin [37] and the continued activation of focal adhesion kinase and extracellular-regulated kinase, which can promote enhanced survival and proliferation of erythroid progenitors [38] . e activation of α5β1 integrin by VEGFR-2 may also increase vascular precursor migration as a result of prolonged extracellular-regulated kinase activation [39] . It is possible that when the α5β1 integrin and VEGF bindbronectin in close proximity, bronectin acts as a "chaperone" to support the sustained binding of VEGF to VEGFR-2 while simultaneously engaging α5β1 [28] . As such, when bronectin and VEGF are bound to their cognate receptors, cellular responses to VEGF are enhanced [35] .
Based on the idea that there is an important interaction between the α5β1 integrin and VEGF in a bronectin-rich environment, α5β1 integrin may be an important target for therapies aimed at preventing or slowing metastatic tumor growth. Indeed, preclinical models have suggested that selective antagonists of α5β1 integrin can reverse tumor growth [40, 41] and these inhibitors have been studied in preliminary clinical trials [42] . ese inhibitors are thought to lead to endothelial cell apoptosis via anoikis, a form of cell death induced by anchorage-dependent cells detaching from the surrounding extracellular matrix, thereby depriving ECs from essential signals for growth and survival [40, 41] .
Although VEGF may have an important role in the setting of cancer, we recognize that it is elevated in other in ammatory conditions and is implicated in other biological processes. For instance, VEGF expression can be up-regulated in vascular cells at sites of in ammation in response to basic broblast growth factor, which is released by the action of proteases and heparinases found on the extracellular matrix [43] . In addition, uterine activation during labor is associated with increased production of pro-in ammatory cytokines which increase the synthesis of VEGF [44] . Additional studies in patients with acute tissue injury may provide insight regarding the speci city of the pattern of VPC cluster formation on bronectin that we observed in cancer patients in our study.
De ning cell populations most enriched for vascular precursor activity has been challenging. It appears VPC clusters include a heterogenous cell population and speci c cell surface molecules that allow for the prospective isolation of pure VPC populations in humans or other vertebrate species is lacking [45] . Moreover, the precise origin, proliferative potential and di erentiation capacity of cells contributing to clusters observed using the VPC assay, also referred to as the CFU-Hill assay, has been recently summarized [46, 47] . It appears that several cell types from di erent cell lineages likely contribute to neovascularisation during normal conditions and during disease. Chief among these angiogenic cell types are bloodderived monocytes that can form spindle-shaped attaching cells in the VPC assay [10] [11] [12] . Although there is a well described correlation between various health outcomes and the number of VPC clusters measured using the VPC assay, the relevance and impact of our observations requires con rmation using in vivo models where the extracellular matrix can be manipulated.
e VPC assay, also referred as the CFU-Hill method, does not assess vessel-forming capacity which may limit its physiological relevance. Importantly, VPC assays typically use bronectin alone and may not re ect the full scope of vascular progenitor function. In addition, other cell types associated with vascular repair may need to be examined to understand the full spectrum of integrin-mediated binding of vascular precursors to the extracellular matrix during health and in cancer patients. Additionally, the relatively small number of patient samples used in our study limits our ability to consider other variables which could in uence VPC cluster formation. More study is required in a broader range of tumor types, in patients with various stages of cancer, and at di erent time points during treatment to con rm our observations and to appreciate the full scope of our ndings. Moreover, advanced age [48] , diabetes [49] , smoking [50] and certain medications such as HMG-co reductase inhibitors [51] are known to in uence the number of VPC clusters in the peripheral blood. Larger cohorts of patients will be needed to perform multivariable analysis of clinical factors that may in uence the pattern of VPC cluster formation. Our results using the VPC cluster assay, however, provide a foundation for better understanding interactions between VPCs and extracellular matrix proteins.
In summary, our work suggests distinct pro les of VPC cluster formation seem to occur in cancer patients and our observations highlight the importance of integrin-speci c binding of attaching cells to extracellular matrix proteins. VEGF Labonté et al. Vascular progenitors and ECM binding in cancer appears to be a key determinant in facilitating integrinmediated binding to bronectin through the α5β1 integrin.
e downstream signaling e ects of speci c matrix proteins, such as laminin and bronectin, which bind speci c integrins on cells of the vascular repair system, require further investigation to better understand how mechanisms associated with tumor angiogenesis are distinct from normal repair processes.
